Adalimumab drug survival in patients with psoriasis, Crohn's disease, and rheumatoid arthritis: Relevant differences using the same treatment - 18/12/15
Doi : 10.1016/j.jaad.2015.08.010
Juul M.P.A. van den Reek, MD a, ⁎ 
, Philippe A.R.R. Pijls, MD b, Marcia Tummers, PhD d, Piet C.L.M. van Riel, MD, PhD c, Wietske Kievit, PhD d, Frank Hoentjen, MD, PhD b, Elke M.G.J. de Jong, MD, PhD a
, Philippe A.R.R. Pijls, MD b, Marcia Tummers, PhD d, Piet C.L.M. van Riel, MD, PhD c, Wietske Kievit, PhD d, Frank Hoentjen, MD, PhD b, Elke M.G.J. de Jong, MD, PhD a a Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands
b Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands
c Scientific Institute for Quality of Healthcare, Radboud University Medical Center, Nijmegen, The Netherlands
d Radboud Institute for Health Sciences, Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands
∗Correspondence to: Juul M. P. A. van den Reek, MD, Radboud University Medical Center, Department of Gastroenterology/Dermatology, Geert Grooteplein 10, 6525 GA Nijmegen, The Netherlands
| Juul M. P. A. van den Reek and Philippe A. R. R. Pijls share first authorship. |
|
| Funding sources: The BioCAPTURE registry is Supported by University Medical Centre St Radboud Foundation, which received funding from Pfizer, Janssen, and AbbVie for the project. Pfizer, Janssen, and AbbVie played no role in the design and execution of the study or in data collection, data management, data analysis, interpretation of the data, manuscript preparation, manuscript review, or manuscript approval. |
|
| The registry was approved by our medical ethics committee. According to Dutch law, informed consent was not mandatory for this noninterventional study; however, it is obtained from every newly included patient. |
|
| Conflicts of interest: J.M.P.A. van den Reek carries out clinical trials for AbbVie and Janssen. J.M.P.A. van den Reek has received speaking fees from AbbVie and Eli Lilly and reimbursement for attending symposia from Janssen, Pfizer, and AbbVie. E.M.G.J. de Jong has received research grants for the independent research fund of the Department of Dermatology of the University Medical Center St Radboud, Nijmegen, The Netherlands, from AbbVie, Pfizer, and Janssen, and has acted as a consultant and/or paid speaker for and/or participated in research sponsored by companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Janssen, Pfizer, and Merck, Sharp & Dohme. |
© 2015
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 74 - N° 1
P. 177-179 - janvier 2016 Retour au numéro
Article précédent
- Effectiveness of sequential use of biologics in the treatment of moderate to severe psoriasis in real world Canadian academic clinical practice: A cohort study
- Judy K. Qiang, Ali Shahbaz, Whan Kim, Joseph Marinas, Simon Greaves, Jensen Yeung
- Compliance with the College of American Pathologists Protocol for Melanoma in Synoptic and Non-Synoptic reports: A cross-sectional study
- Alexander Maley, Samit Patrawala, Benjamin Stoff
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?